Martha J Demski
CIK 1198230 · last filed 2026-07-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CMRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92122
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TKNO | Director | 12,000 | $6.63 | $79.6K | -$40.5K | 7 | 2026-07-16 |
| EQ | Director | — | $1.24 | — | $0 | 9 | 2026-05-29 |
| CHIMERIX INC (CMRX) Delisted | Director | 0 | $8.54 | $0 | -$781.3K | 32 | 2025-04-21 |
| ADMA | Director | 56,601 | $10.98 | $621.5K | $10.8K | 6 | 2023-03-08 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Director | 0 | $8.22 | $0 | -$10.3K | 9 | 2021-11-24 |
| Evofem Biosciences, Inc. (NEOT) Delisted | Director | 2,732 | — | — | $0 | 4 | 2017-06-21 |
Recent Filings · Page 3 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-03-09 | ADMA | Grant (A) | +26,586 | $0 | EDGAR |
| 2021-11-24 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Mixed | −21,000 | $0 | EDGAR |
| 2021-06-25 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-08 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Sell (S) | −2,000 | -$10.3K | EDGAR |
| 2021-06-04 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2021-05-28 | EQ | Grant (A) | — | $0 | EDGAR |
| 2021-03-01 | ADMA | Grant (A) | — | $0 | EDGAR |
| 2020-11-19 | CHIMERIX INC (CMRX) Delisted | Mixed | +7,042 | $16.5K | EDGAR |
| 2020-09-14 | ADMA | Buy (P) | +2,200 | $5.0K | EDGAR |
| 2020-08-14 | ADMA | Buy (P) | +2,000 | $5.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.